TScan Therapeutics Inc (TCRX)

[crudeoil24]

Recent IPO > Tscan Therapeutics Inc is a United States-based preclinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. TScan is engaged in advancing a pipeline of TCR-T therapy candidates for the treatment of patients with hematologic and solid tumor malignancies. Its lead liquid tumor product candidates, TSC-100 and TSC-101, are under development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. TScan solid tumor product candidates include TSC-200, TSC-201, TSC-202 and TSC-203. The Company's solid tumor TCR-T therapy candidates include a combination of known targets, such as HPV16 for TSC-200 and Preferentially Expressed Antigen in Melanoma (PRAME) for TSC-203. The Company's platform technologies include TargetScan, ReceptorScan and T-Integrate.